BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
TEL AVIV, Israel, March 07, 2017 -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders, today announced that management will participate in two upcoming investor healthcare conferences during March.
29th Annual ROTH Conference
Date: Tuesday, March 14
Time: 4:00 PM PDT
Location: Ritz Carlton Laguna Niguel, Orange County, CA
Oppenheimer 27th Annual Healthcare Conference
Date: Wednesday, March 22
Time: 9:45 AM EDT
Location: Westin Grand Central, New York, NY
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of medications to treat CNS and cognitive disorders. For more information, please visit the company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
Investor Contacts Alcobra Investor Relations Debbie Kaye US: 212-390-8964, Intl: +972-3-7299871 [email protected]
